BioXcel Therapeutics forms neuroscience CAB for BXCL501
BioXcel Therapeutics announced the formation of a Clinical Advisory Board, or CAB, to provide strategic counsel to the company as it advances the development of BXCL501, a first-in-class sublingual thin film formulation of Dexmedetomedine, for the treatment of agitation. Additionally, the CAB will support the advancement of further candidates in BTI's emerging neuroscience pipeline identified through its artificial intelligence innovation lab partnership with BioXcel Corporation. The initial members of the CAB include: Prof. Sheldon H. Preskorn, M.D.; Prof. Stephen Marder, M.D.; Dr. George Grossberg, M.D. and Prof. Alan Breier, M.D. The Company expects to add other neuroscience leaders going forward.